Why is AstraZeneca is Investing $50bn into the US?
In the wake of President Trump's extensive and disruptive programme of tariffs, several corporations have initiated significant investments in the US.
AstraZeneca, the UK-based pharmaceutical giant, plans to invest a remarkable US$50bn in US research and manufacturing capabilities by 2030.
This strategic move is aimed at mitigating the risks and uncertainties that the tariffs have imposed on international pharmaceutical enterprises.
Tariffs and their impact
With President Trump delivering a sustained period of tariffs, the landscape for global trade has become increasingly complex.
Sectors such as pharmaceuticals and the automotive industry have been particularly targeted with these tariffs, as well as specific country tariffs that have been introduced such as 35% for Canadian imports and 50% for Brazilian goods.
More specifically, President Trump has articulated plans for a steep 200% tariff on foreign-made drugs, pushing companies worldwide to reconsider their manufacturing locations.
During a press interaction mid-July, Trump shared that “Pharmaceuticals will be tariffed, probably at the end of the month, and we’re going to start off with a low tariff and give the pharmaceutical companies a year or so to build and then we’re going to make it a very high tariff.”
This statement underscores a one-year grace period followed by a significant increase in tariffs, further pressuring global pharmaceutical operations.
AstraZeneca's strategic investment
In response to these tariffs, AstraZeneca, based in Cambridge, has committed to investing US$50bn into US manufacturing sectors by 2030.
US Commerce Secretary Howard Lutnick said: "We are proud that AstraZeneca has made the decision to bring substantial pharmaceutical production to our shores. This historic investment is bringing tens of thousands of jobs to the US and will ensure medicine sold in our country is produced right here."
This expansive investment targets the establishment of new drug manufacturing units in Virginia and the augmentation of R&D and cell therapy capabilities in Maryland, Massachusetts, California, Indiana and Texas.
The anticipated revenue increase from US$54.1bn in 2024 to US$80bn by 2030 is expected to be supported significantly by a fortified US market presence.
Sir Pascal Soriot, CEO of AstraZeneca, commented that this move reflects the company's “belief in America’s innovation in biopharmaceuticals and our commitment to the millions of patients who need our medicines in America and globally.”
Michel Demaré, Chair of AstraZeneca, added: "Central to this investment is a proposed new, state-of-the-art drug substance manufacturing facility in Virginia focused on chronic diseases, which is set to be our largest manufacturing investment to date."
US manufacturing expansion rises in the pharmaceutical industry
AstraZeneca is not alone in its US expansion.
Other pharmaceutical leaders, such as Swiss company Roche, have announced an investment of US$50bn for US manufacturing investment aimed at creating numerous jobs.
Similarly, Novartis plans to allocate US$23bn towards its US operations.
Concurrently, American giants like Johnson & Johnson are committing US$55bn to manufacturing and R&D ventures.
This shift in location is not exclusive to the pharmaceutical industry.
Apple has publicised a significant US$500bn investment in the US.
As Trump's tariffs continue to reshape global trade strategies, businesses worldwide are recalibrating operations, devising innovative manufacturing and supply chain solutions that secure their market positions amid these economic policies.
